Edwards Lifesciences price target raised to $96 from $86 at Canaccord Canaccord raised its price target on Edwards Lifesciences (EW) to $96 based on the worldwide patent litigation settlement with Medtronic (MDT). The firm believes the agreement removes an expensive distraction for the business and retains the goodwill of physicians. Shares are Buy rated.
Edwards Lifesciences announces outcomes for patients treated with SAPIEN 3 valve Edwards Lifesciences announced that 30-day outcomes for intermediate-risk patients treated transfemorally with the SAPIEN 3 transcatheter aortic valve at centers in Europe and Canada demonstrated very low mortality and stroke rates, and no severe paravalvular leaks. These independently adjudicated data are consistent with the outcomes recently reported in a similar study of 1,000 patients treated at 51 centers in the United States. In the multi-center study of 101 intermediate-risk patients, all-cause mortality was 1 percent. The frequency of other important complications was also low: the disabling stroke rate was 2 percent, major vascular complications were 2 percent and the permanent pacemaker rate was 4 percent. The investigators also noted that the SAPIEN 3 valve had excellent hemodynamic performance, with very low incidence of significant paravalvular regurgitation, as only 2.3 percent of patients had moderate paravalvular leaks and there were no reports of severe leaks.